Search
Arbutus Biopharma Corp
ABUSAdd to Watchlist
4.870USD
+0.140+2.96%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
959.14MMarket Cap
5.87P/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+2.96%
5 Days
+9.19%
1 Month
+8.71%
6 Months
+2.10%
Year to Date
+1.25%
1 Year
+53.14%
Key Figures
4.770Open
4.955High
2.60MVolume
5.87P/E TTM
LossP/E Dynamic
--Dividend TTM
1.32%Turnover Ratio
4.730Prev. Close
4.745Low
9.50MTurnover
LossP/E Static
3.69P/B
0.00%Div Yield TTM
81.55%ROA
5.10052wk High
1.31Volume Ratio
-69.92MNet Profit
196.95MShares
0.8295EPS TTM
0.63Beta
94.73%ROE
3.04052wk Low
4.44%Amplitude
100.00%Gross Margin
959.14MMarket Cap
3.23Reward/Risk
2.71%Risk Rate
TradingKey Stock Score of Arbutus Biopharma Corp
Currency: USD Updated: 2026-07-01Key Insights
Arbutus Biopharma Corp's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 30 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 5.17.In the medium term, the stock price is expected to remain stable.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Arbutus Biopharma Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Arbutus Biopharma Corp Highlights
StrengthsRisks
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on infectious disease. The Company is developing imdusiran (AB-729), its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). Its HBV product pipeline includes Imdusiran and AB-101. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for. PD-L1 inhibitors complement its pipeline of agents and could potentially be a part of a combination therapy for the treatment of HBV by reawakening the immune system.
Growing
The company is in a growing phase, with the latest annual income totaling USD 14.08M.
Overvalued
The company’s latest PE is 5.70, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 128.81M shares, increasing 4.98% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 16.80K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.83.
Analyst Rating
Based on
3
analysts
Buy
Current Rating
5.167
Target Price
+10.40%
Upside Space
Arbutus Biopharma Corp News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Arbutus Biopharma Corp Info
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on infectious disease. The Company is developing imdusiran (AB-729), its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). Its HBV product pipeline includes Imdusiran and AB-101. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for. PD-L1 inhibitors complement its pipeline of agents and could potentially be a part of a combination therapy for the treatment of HBV by reawakening the immune system.
Ticker SymbolABUS
CompanyArbutus Biopharma Corp
CEOAndroski (Lindsay)
Websitehttps://www.arbutusbio.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+2.95%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
FAQs
What is the current price of Arbutus Biopharma Corp (ABUS)?
The current price of Arbutus Biopharma Corp (ABUS) is 4.73.
What is the symbol of Arbutus Biopharma Corp?
The ticker symbol of Arbutus Biopharma Corp is ABUS.
What is the 52-week high of Arbutus Biopharma Corp?
The 52-week high of Arbutus Biopharma Corp is 5.10.
What is the 52-week low of Arbutus Biopharma Corp?
The 52-week low of Arbutus Biopharma Corp is 3.04.
What is the market capitalization of Arbutus Biopharma Corp?
The market capitalization of Arbutus Biopharma Corp is 934.35M.
Is Arbutus Biopharma Corp (ABUS) currently rated as Buy, Hold, or Sell?
According to analysts, Arbutus Biopharma Corp (ABUS) has an overall rating of Buy, with a price target of 5.17.
What is the Earnings Per Share (EPS TTM) of Arbutus Biopharma Corp (ABUS)?
The Earnings Per Share (EPS TTM) of Arbutus Biopharma Corp (ABUS) is -0.17.